IBM Reportedly Shopping Watson Health Amid Healthcare Industry Growth

IBM's Potential Sale of Watson Health: A Reassessment

Reports from Axios suggest that IBM may be preparing to sell its Watson Health division for approximately $1 billion. This raises questions regarding IBM’s strategic shift away from the healthcare sector, particularly given the current surge in investment within the industry, and the comparatively low valuation.

Recent Healthcare Acquisitions by Tech Giants

The timing of this potential sale is noteworthy. Just recently, Oracle completed the acquisition of digital health records firm Cerner for $28 billion. Previously, Microsoft invested nearly $20 billion in Nuance, a company with a substantial presence in the medical field, serving 10,000 healthcare clients.

These substantial investments demonstrate a clear trend: major enterprise companies are actively seeking to expand their involvement in healthcare and are willing to allocate significant capital to achieve this.

The Initial Promise of Watson Health

IBM initially launched Watson Health in April 2015, generating considerable excitement. The core concept involved leveraging IBM’s Watson artificial intelligence platform to address challenges within the healthcare landscape.

The underlying premise was that even highly skilled physicians are limited in their capacity to process the vast amount of medical literature available. A computer, however, could rapidly analyze this information and provide data-driven recommendations to enhance a doctor’s expertise and improve patient outcomes.

Early Investments and Partnerships

Following the launch, IBM invested heavily in Watson Health. A dedicated headquarters was established in Cambridge in September 2015.

Furthermore, the company actively pursued strategic partnerships with prominent organizations, including CVS, Apple, and Johnson & Johnson, fulfilling key milestones in its initial strategy.

Acquisitions to Fuel Data-Driven Insights

IBM then embarked on a series of acquisitions aimed at bolstering Watson Health’s data capabilities. The initial purchases included medical data companies, Phytel and Explorys.

This pattern continued with the $1 billion acquisition of Merge Healthcare, a provider of medical imaging data. Subsequently, IBM made its largest investment, acquiring Truven Health Analytics for $2.6 billion. In total, these acquisitions amounted to $4 billion, a figure that appears modest in comparison to the recent expenditures of Oracle and Microsoft, but represented a significant investment in 2015 and 2016.

The Data-Centric Approach and its Challenges

The strategy centered on utilizing a data-centric approach to train Watson Health’s machine learning models. Despite these efforts, the anticipated results did not fully materialize.

However, it was a central component of former CEO Ginni Rometty’s vision for modernizing IBM by concentrating on areas such as cloud computing and artificial intelligence.

Former CEO's Optimism

In a 2017 interview with the Harvard Business Review, Rometty expressed optimism regarding the future of Watson Health.

A Shift in Priorities Under New Leadership

Rometty stepped down in 2019, and her successor, Arvind Krishna, has adopted a different strategic direction. Krishna indicated to Axios that the initial broad healthcare vision may have been overly ambitious.

According to Holger Mueller, an analyst at Constellation Research, this shift in perspective could explain IBM’s desire to divest from Watson Health.

Focus on Hybrid Cloud Strategy

“IBM is prioritizing its hybrid cloud strategy and is actively seeking to divest assets that divert attention and capital, as well as potentially damage its reputation,” Mueller explained. “Watson Health clearly meets all three of these criteria, making its potential divestiture unsurprising.”

A Potential Failed Strategy

Even if IBM continues to pursue healthcare opportunities through other divisions, the potential sale of Watson Health would likely be viewed as a strategic failure, given the substantial investment and limited returns.

It is important to note that this remains a rumor, although its realization would not be unexpected.